Tower Research Capital LLC TRC Sells 5,225 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Tower Research Capital LLC TRC cut its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 69.8% in the fourth quarter, HoldingsChannel reports. The firm owned 2,259 shares of the company’s stock after selling 5,225 shares during the period. Tower Research Capital LLC TRC’s holdings in USANA Health Sciences were worth $81,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Pzena Investment Management LLC increased its holdings in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock valued at $39,015,000 after buying an additional 37,466 shares during the period. Dimensional Fund Advisors LP raised its position in shares of USANA Health Sciences by 7.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock worth $27,751,000 after acquiring an additional 55,059 shares in the last quarter. Pacer Advisors Inc. lifted its stake in shares of USANA Health Sciences by 8.8% during the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock worth $21,247,000 after purchasing an additional 47,745 shares during the last quarter. Geode Capital Management LLC boosted its position in USANA Health Sciences by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 301,949 shares of the company’s stock valued at $10,839,000 after purchasing an additional 4,829 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in USANA Health Sciences by 12.3% in the fourth quarter. American Century Companies Inc. now owns 233,797 shares of the company’s stock valued at $8,391,000 after purchasing an additional 25,522 shares during the last quarter. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at USANA Health Sciences

In other news, insider Joshua Foukas sold 5,732 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jim Brown sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total transaction of $147,350.00. Following the sale, the chief executive officer now directly owns 15,716 shares in the company, valued at $463,150.52. The trade was a 24.14 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,594 shares of company stock worth $520,384. 0.63% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have commented on USNA. DA Davidson decreased their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Finally, Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

USANA Health Sciences Stock Performance

Shares of NYSE USNA opened at $29.52 on Friday. USANA Health Sciences, Inc. has a fifty-two week low of $23.10 and a fifty-two week high of $49.78. The company has a market cap of $549.75 million, a PE ratio of 10.43, a P/E/G ratio of 0.93 and a beta of 0.60. The business has a 50-day simple moving average of $27.34 and a two-hundred day simple moving average of $32.69.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. During the same quarter in the previous year, the firm earned $0.86 EPS. On average, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.